1. Center for Drug Evaluation and Research . NDA 20-687. Approval Letter for MIFEPREX (mifepristone) Tablets, 200 mg to Population Council. Food and Drug Administration. Written September 28, 2000. Accessed November 18, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/20687appltr.htm
Google Scholar2. FDA Adverse Event Reporting System (FAERS) Public Dashboard. FDA. Updated October 22, 2021. Accessed November 11, 2021. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
Google Scholar3. What is FOIA? US Dept of Justice. FOIA. Accessed November 16, 2021. https://www.foia.gov/about.html
Google Scholar4. Cleland, K, Creinin, MD, Nucatola, D, Nshom, M, Trussell, J. Significant adverse events and outcomes after medical abortion. Obstet Gynecol. 2013;121(1):166‐171. https://doi.org/10.1097/aog.0b013e3182755763
Google Scholar | Crossref | Medline5. Aultman, K, Cirucci, C, Harrison, D, et al. Deaths and severe adverse events after the Use of mifepristone as an abortifacient from September 2000 to February 2019. Issues Law Med. 2021;36(1):326. https://issuesinlawandmedicine.com/wp-content/uploads/2021/01/Deaths-and-Severe-Adverse-Events-after-the-use-of-Mifepristone-as-an-Abortifacient-from-September-2000-to-February-2019-copy5.pdf.
Google Scholar6. Gary, MM, Harrison, DJ. Analysis of severe adverse events related to the Use of mifepristone as an abortifacient. Ann Pharmacother. 2006;40(2):191‐197. https://doi.org/10.1345/aph.1G481
Google Scholar | SAGE Journals | ISI7. Communities Need Clinics: The Essential Role of Independent Abortion Clinics in the United States . Abortion Care Network. 2020:2. Accessed November 15, 2021. https://abortioncarenetwork.org/wp-content/uploads/2020/12/CommunitiesNeedClinics-2020.pdf.
Google Scholar8. National Academies of Sciences, Engineering, and Medicine . The Safety and Quality of Abortion Care in the United States. The National Academies Press; 2018: Kindle Locations 1351–1367. Accessed 11–29–21. https://doi.org/10.17226/24950
Google Scholar9. Gill, R, Norman, WV. Telemedicine and medical abortion: dispelling safety myths, with facts. Mhealth. 2018;4(3):1–4. https://doi.org/10.21037/mhealth.2018.01.01
Google Scholar | Medline10. Upadhyay, UD, Schroeder, R, Roberts, SCM. Adoption of no-test and telehealth medication abortion care among independent abortion providers in response to COVID-19. Contracept X. 2020;2(100049):1–5. https://doi.org/10.1016/j.conx.2020.100049
Google Scholar11. Gatter, M, Cleland, K, Nucatola, DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception. 2015;91(4):269‐273. https://doi.org/10.1016/j.contraception.2015.01.005
Google Scholar | Crossref | Medline12. Food and Drug Administration . Information on Mifeprex Labeling Changes and Ongoing Monitoring Efforts. GAO-18-292 Report to Congressional Requesters. March 2018:8. Accessed November 30, 2021. https://www.gao.gov/assets/700/690914.pdf
Google Scholar13. Letter from Woodcock J . (Acting Commissioner of Food and Drugs) to Phipps MG (Chief Executive Officer ACOG) and Grobman, W (Pres Society for Fetal-Maternal Medicine). ACLU. April 12, 2021. p. 2. Accessed November 15, 2021. https://www.aclu.org/sites/default/files/field_document/fda_acting_commissioner_letter_to_acog_april_12_2021.pdf
Google Scholar14. Letter to Joseph R. Biden (President of the US) from the ACLU and others . Planned Parenthood. March 18, 2021. 1-5. Accessed November 30, 2021. https://www.plannedparenthood.org/uploads/filer_public/28/b2/28b21706-7f25-4cd6-b43b-ee340a6681d7/coalition_letter_to_biden_administration_re_mifepristone_3_18_21_final.pdf
Google Scholar15. Chelius v. Becerra, Case 1:17-cv-00493-JAO-RT . Document 148. P. 3191. (DC Hawaii) July 9, 2021. Accessed November 30, 2021. https://www.aclu.org/sites/default/files/field_document/chelius_v._becerra_-_joint_motion_for_stay_pending_agency_review_may_7_2021.pdf
Google Scholar